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outgrowth. So the difference in the expres-
sion profile between our c-kit1 cells and
that detected by Pouly and colleagues1 can-
not be the result of cell processing.
Our findings indicate that c-kit1 cells,
present in right atrial appendages, coexpress
CD105 but are CD452. It is therefore un-
likely that these cells are mast cells because
our data indicate that they are probably car-
diac progenitor cells.
Remco Koninckx, MSc
Karen Hensen, PhD
Jean-Luc Rummens, MD
Marc Hendrikx, MD
Virga Jesse Hospital, Hasselt, Belgium and
University of Hasselt, Diepenbeek, Belgium
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Reply to the Editor:
We thank Koninckx and colleagues for their
comments. As stated in our article, data
were obtained from both endomyocardial bi-
opsies and atrial appendages, and these 2
sampling sites yielded concordant data.
However, themajor difference is thatwe per-
formed in situ detection and characterization
of cells, whereas Koninckx and colleagues
cultured cells for 2 weeks before immunos-
tainings. Such a time interval can change
the cell phenotype and delete some cell pop-
ulations thatdonotsurviveunderthesecondi-
tions. The latter phenomenon could explain
why Koninckx and colleagues did not find
any mast cell in their myocardial tissue cul-
tures, whereas it is well established that the
myocardium does contain such cells. Be-
causeaminorcomponentof thec-kit-positive
cells could have represented a subset of cells
different frommast cells, we also tested them
for other markers of stemness (CD105, islet-
1, andMDR1). However, in our hands, these
markers remained negative. The data of
Koninckx and colleagues suggest that after
a period of culture, c-kit-positive cardiac
‘‘stem’’ cells can be identified, but it would
beclinicallyrelevantthat theyprovideaquan-
titative estimate of these cells to assess
whether thisnumberallowsonetoreasonably
envision their use for therapeutic purposes.
Julia Pouly, MD
Patrick Bruneval, MD
Philippe Menasche, MD, PhD
Hopital Europeen Georges Pompidou
Department of Cardiovascular Surgery
Paris, France
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Figure 1. Immunofluorescent staining on cells
grown out of cardiac tissue. Cells incubated
with CD45-FITC (A, lower left) and C-kit-phycoer-
ythrin (A, upper right). 4,6-diamino-2-phenylindole
(A and B, upper left) was used to stain nuclei. A,
Outgrown c-kit1 cells do not coexpress CD45
and c-kit. B, Cells are incubated with CD105-
FITC (lower left) and c-kit-phycoerythrin (upper
right); 95% of the cells do express CD105 and
a subpopulation coexpresses c-kit. DAPI, 4,6-dia-
mino-2-phenylindole.
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To the Editor:
I write to comment on the editorials by Drs
Sundt1 (April 2008) and Westaby2 (March
2008). Dr Sundt is perceptive but fails to
consider that the observational studies sug-
gesting a danger with aprotinin may have
had bias in the analysis.
At the advisory committee meeting of
the Food and Drug Administration (FDA)
held on September 12, 2007, Dr Mangano
allowed the FDA access to the McSPI
(Multicenter Study of Perioperative Ische-
mia) data set. Whereas Mangano and col-ascular Surgery c September 2008leagues3 used a propensity score that was
based on likelihood of bleeding, the FDA
reanalysis of these data used stratification
according to risk of adverse outcome. The
FDA analysis showed no increases in rela-
tive risks (RRs) for death (RR 0.91, 95%
confidence interval [CI] 0.54–1.53), heart
failure (RR 1.05, 95% CI 0.75–1.47), myo-
cardial infarction (RR 1.10, 95% CI 0.88—
1.39), or renal dysfunction (RR 1.26, 95%
CI 0.76–2.11) when data from 1222 aproti-
nin-treated patients were compared with
those of 1307 patients who did not receive
the drug.4
At the same FDA meeting, Dr Karkouti,
who used matching of pairs of data, showed
that the inclusion into the model of cardio-
pulmonary bypass variables (time and circu-
latory arrest) and transfusion (.4 units of
red blood cells and fresh-frozen plasma)
removed the statistical effects of aprotinin
on renal function.4 The Toronto data have
never shown any other mortality or morbid-
ity risk. Dr Funary also presented the North
West Consortium analysis, which showed
that any apparent effect of aprotinin on
adverse outcome is lost when red blood
cell transfusion numbers are included as
a confounding variable.5
In the article from Shaw and col-
leagues6 of the Duke University Medical
Center, the populations of patients rec-
eiving aprotinin or e-aminocaproic acid
(EACA) were hugely different. No matter
how clever the statistical modeling, cli-
nicians will recognize that there must be
differences in management and outcome
between a patient with isolated myocardial
ischemia undergoing primary, elective
revascularization (given EACA) and one
undergoing a nonelective reoperation for
heart failure associated with valve pathol-
ogy (who would likely receive aprotinin
in about 70%-80% of cases worldwide).
Despite this, Shaw and colleagues6
Reply to the Editor:
I appreciate Dr Royston’s kind comment re-
garding my editorial. I am quite certain that
he agrees with me that we are ‘‘worse off
without [aprotinin] in our arsenal.’’ Indeed,
I feel this sentiment particularly this even-
ing, as I wait for a call from the operating
room to start repair of an acute dissection
in an 80-year-old patient who is receiving
warfarin 5 years after coronary bypass and
aortic valve replacement. I am also sure
that he agrees that, in the best of all possible
worlds, the risks and benefits determining
the use of a drug should pertain to the wel-
fare of the patient as judged by physicians
and not to the litigation risks of a pharmaceu-
tical company as judged by lawyers.
I also appreciate Dr Royston’s comments
regarding bias. The biases of which he
speaks have not (entirely) escaped me; all
studies have biases. Randomized studies
are of necessity biased at entry. Rigid eligi-
bility criteria are necessary to define a popu-
lation with sufficient precision to permit
analysis, and the demands of equipoise
encourage inclusion of low-risk patients for
whom harm is the least likely–but so is ben-
efit. Consequently, few such studies truly re-
flect the spectrum of disease that we face in
clinical practice. The populations included
in observational studies are more representa-
tive of practice; however, the bias introduced
by the clinical judgments made in the appli-
cation of a therapy or administration of
a drug impose considerable challenges to
balanced interpretation, as so beautifully
demonstrated in Dr Royston’s letter. I could
not agree more. As noted in his comments,
understanding the appropriate application
and interpretation of propensity analysis de-
mands a learned understanding of the
methods as well as the aims of the matching.
Unfortunately, few of us (certainly not I) are
so statistically sophisticated. I know that in
this regard Dr Royston can run circles
around me. No contest.
In the end, where we differ, it would
appear, is regarding just where the rest of
the medical community is struggling. What
are the real risks associated with aprotinin?
Is it ‘‘a potentially harmful drug’’? If so,
what is the magnitude of that risk? Person-
ally, I remain amazed that today (May
23, 2008), with more than 7100 citations
now retrievable on a PubMed search for
aprotinin, there is still room for debate.
Thoralf M. Sundt, MD
Division of Cardiovascular Surgery
Mayo Clinic
Rochester, Minn
doi:10.1016/j.jtcvs.2008.06.005
Letters to the Editorconcluded that aprotinin use was the factor
associated with mortality when comparing
data from 1343 aprotinin-treated patients
with those from 6776 given EACA and
2029 given neither therapy.
Two aspects may lead the interested
reader to question this conclusion. First,
the propensity analysis did not include red
blood cell transfusion numbers as a factor
(transfusion was graded as either yes or
no). More worrisome is that a matched-pairs
analysis was relegated to the supplementary
data available online from the New England
Journal of Medicine. In this analysis, which
included 1992 patients with comparable
risks, aprotinin showed no effects on 30-
day (P 5 .58) and 1-year mortalities (P 5
.36) relative to EACA.
Thus if propensity scoring is achieved by
linear regression, and confounding variables
known to be associated with adverse out-
comes are excluded, then observational
studies show aprotinin to be a dangerous
drug. Aprotinin is not seen to be dangerous,
however, when the analysis is performed
with matching or stratification of risk and
known confounders are included.
David Royston, FRCA
Consultant Anaesthetist
Royal Brompton and Harefield NHS Trust
Harefield, UK
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